News Column

Arch Scientists Publish Data Linking Inflammatory Enzymes to Inflammatory Bowel Disease

Apr 3 2013 12:00AM

Marketwire

LogoTracker

TORONTO, ONTARIO -- (Marketwired) -- 04/03/13 -- Arch Biopartners Inc ("Arch" or the "Company") (CNSX: ACH)(OTCBB: FOIFF) today announced that Arch scientists have co-authored a paper disclosing findings that links inflammatory bowel disease ("IBD") to caspase 1, a key enzyme that regulates inflammation and cell homeostasis in the gut. The Arch scientists are using these novel findings to develop new diagnostic tests to monitor IBD activity, response to treatment and to differentiate IBD from conditions such as irritable bowel syndrome ("IBS").

University of Alberta scientist Dr. Julia Liu and Arch scientists Dr. Randall Irvin, Dr. Daniel Muruve and Dr. Elisabeth Davis are among the co-authors of a paper published in the journal Inflammatory Bowel Diseases titled "Epithelial Cell Extrusion Leads to Breaches in the Intestinal Epithelium" and can be accessed at:

http://www.ncbi.nlm.nih.gov/pubmed/23511029

In their publication, the investigators show that inflammatory enzyme activation in intestinal epithelial cells leads to changes in intestinal epithelium integrity and increased intestinal permeability, a central feature of IBD.

About IBD and IBS

IBD is a chronic disorder of the gastrointestinal tract, including Crohn's disease or ulcerative colitis, characterized by inflammation of the intestine and resulting in abdominal cramping and persistent diarrhea. According to the Crohn's and Colitis Foundation, approximately 1.4M Americans suffer from IBD. Current methods used to diagnose IBD include endoscopy, pill endoscopy and CT scans.

IBS is a condition of the bowel that also causes frequent abdominal discomfort, pain and diarrhea. IBS affects approximately 10% of the world's population and there is no readily available diagnostic test for IBS. Doctors generally perform a battery of tests to exclude all other causes of abdominal discomfort before giving the clinical diagnosis of IBS.

As a result, a common clinical problem is the inability to easily differentiate IBD from IBS. In addition, there is no generally accepted, objective method for monitoring IBD and the effectiveness of its treatment.

About Arch Biopartners

Arch Biopartners is a portfolio based technology company established to develop new products and technology for sale to pharmaceutical and industrial companies.

For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.

The Company's website address is: www.archbiopartners.com.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.



Contacts:
Arch Biopartners Inc.
Richard Muruve
CEO
(647) 428 7031
info@archbiopartners.com
www.archbiopartners.com





Source: Marketwire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters